FUTURE ONCOLOGY
Volume 7 #6/7 August 31, 2003
Meeting Coverage
RANDOMIZED CLINICAL TRIALS WITH NOVEL ANTICANCER AGENTS —
FROM THE 2003 MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
INCREASED EMPHASIS IN ALL ASPECTS OF CLINICAL TRIALS IN ONCOLOGY
- Efforts to Increase Patient Participation
- Streamlining Cancer Drug Development
- Reporting and Registering Clinical Trials
RANDOMIZED AND LARGE CLINICAL TRIALS IN ONCOLOGY
- Ethics of Large Clinical Trials in Oncology
- The Impact of Pharmacogenomics
- Design of Clinical Trials for New Molecularly Targeted Compounds
- Randomized Discontinuation Design
- Relationship Between Response Rate and Survival
OVERSIGHT IN CLINICAL DEVELOPMENT OF ANTICANCER DRUGS
- Centralized Review Boards
- Conflict of Interest Guidelines
DRUG COMBINATION STRATEGIES IN ONCOLOGY
- Colorectal Cancer
- Lung Cancer
- Mesothelioma
- Prostate Cancer
- Biochemotherapy in Metastatic Melanoma
MARKETS OF NEW ANTICANCER DRUGS
NOVEL AGENTS IN RANDOMIZED CLINICAL TRIALS REPORTED AT ASCO03
- Æ-941
- Atrasentan
- Bevacizumab
- BMS-247550
- CeaVac
- CCI-779
- Cetuximab
- Gefitinib
- Irofulven
- LY900003
- Pemetrexed
- Provenge
- PSA-based Vaccine
- Rubitecan
- Satraplatin
- Thalidomide
- Tirapazamine
LIST OF EXHIBITS
Exhibit 1 - Novel Anticancer Agents in Ongoing or Recently Completed Single-agent or Combination, Randomized, Phase III Clinical Trials
Exhibit 2 - Worldwide Markets of Selected Novel Anticancer Agents with Revenues of >$100 Million Introduced Since 1990
Exhibit 3 - Anticancer Agents Granted Accelerated Approval by the FDA (1996-2003)
